½ÃÀ庸°í¼­
»óǰÄÚµå
1684642

ÀÓ»ó½ÃÇè ¹ÙÀÌ¿À¹ðÅ· ¹× ¾ÆÄ«ÀÌºê ¼Ö·ç¼Ç ½ÃÀå : ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®(2025-2034³â)

Clinical Trial Biorepository and Archiving Solutions Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 130 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ÀÓ»ó½ÃÇè ¹ÙÀÌ¿À¹ðÅ· ¹× ¾ÆÄ«ÀÌºê ¼Ö·ç¼Ç ½ÃÀåÀº 2024³â¿¡´Â 46¾ï ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç, 2025³âºÎÅÍ 2034³â¿¡ °ÉÃÄ 8.3%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ·¯ÇÑ ¼ºÀåÀº ÀÓ»ó½ÃÇèÀÇ ±ÞÁõ, ¾ö°ÝÇÑ ±ÔÁ¦ Áؼö ¿ä°Ç, Àå±â µ¥ÀÌÅÍ ÀúÀå¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, °í±Þ ¹ÙÀÌ¿À¹ðÅ· ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ½Å¾à °³¹ß°ú °³ÀÎ ¸ÂÃã ÀÇÇÐÀÇ È¹±âÀûÀÎ ¹ßÀüÀ¸·Î ¹ÙÀÌ¿À Á¦¾à »ê¾÷ÀÌ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó Áß¿äÇÑ »ý¹°ÇÐÀû »ùÇÃÀ» º¸È£ÇÏ´Â ¹ÙÀÌ¿À º¸°ü¼ÒÀÇ ¿ªÇÒÀÌ Çʼö ºÒ°¡°áÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ±Û·Î¹ú ÀÓ»ó½ÃÇèÀÇ ´ë·® ¼ö¿ä¸¦ ÃæÁ·ÇÒ ¼ö ÀÖ´Â Çõ½ÅÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ È®´ëµÇ°í ÀÖÀ½À» °­Á¶ÇÕ´Ï´Ù.

Clinical Trial Biorepository and Archiving Solutions Market-IMG1

¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ÷´Ü Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä·Î ÀÎÇØ Á¦¾à ¹× ¹ÙÀÌ¿À Á¦¾à ȸ»ç´Â ¿¬±¸ °³¹ß ³ë·ÂÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷µéÀº ÀÓ»ó½ÃÇèÀÇ ±ÞÁõ¿¡ ¾ÕÀå¼­°í ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó ÃÖ÷´Ü ¹ÙÀÌ¿À¹ðÅ· ¹× ¾ÆÄ«ÀÌºê ½Ã½ºÅÛ¿¡µµ ¸·´ëÇÑ ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº »õ·Î¿î Ä¡·á¹ýÀÇ ¾ö°ÝÇÑ Å×½ºÆ®¿¡ ÇÊ¿äÇÑ »ý¹°ÇÐÀû »ùÇÃÀÇ Ç°Áú, ¾ÈÀü¼º, ¹«°á¼ºÀ» À¯ÁöÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ ÀÚµ¿È­µÈ º¸°ü ½Ã½ºÅÛ°ú °í±Þ ÃßÀû ±â´É°ú °°Àº ¹ÙÀÌ¿À º¸°ü ¼Ö·ç¼ÇÀÇ ±â¼ú ¹ßÀüÀº ½ÃÀåÀÇ ¸Å·ÂÀ» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 46¾ï ´Þ·¯
¿¹Ãø ±Ý¾× 101¾ï ´Þ·¯
CAGR 8.3%

½ÃÀåÀº Á¦Ç° À¯Çüº°·Î ÀüÀÓ»ó ¹× ÀÓ»ó Á¦Ç°À¸·Î ºÐ·ùµÇ¸ç, 2024³â¿¡´Â ÀÓ»ó Á¦Ç° ºÎ¹®ÀÌ 73.7%ÀÇ ½ÃÀå Á¡À¯À²·Î °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÎ¹®¿¡´Â ½Å¾àÀÇ È¿´É°ú ¾ÈÀü¼ºÀ» Å×½ºÆ®ÇÏ´Â µ¥ ÇʼöÀûÀÎ ÀÎü Á¶Á÷, Àå±â, Áٱ⼼Æ÷ ¹× ±âŸ »ý¹°ÇÐÀû ¹°ÁúÀÌ Æ÷ÇԵ˴ϴÙ. ÀÓ»ó½ÃÇèÀÇ º¹À⼺ÀÌ Áõ°¡Çϰí ÀÌ·¯ÇÑ »ý¹°ÇÐÀû »ùÇÃÀ» º¸Á¸ÇØ¾ß ÇÒ Çʿ伺ÀÌ Ä¿Áö¸é¼­ °ß°íÇÑ º¸°ü ¹× °ü¸® ¼Ö·ç¼ÇÀÇ Á߿伺ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À¹ðÅ· ¹× ¾ÆÄ«ÀÌºê ¼Ö·ç¼ÇÀÇ ÃÖÁ¾ »ç¿ëÀÚ¿¡´Â Á¦¾à ȸ»ç, »ý¸í°øÇРȸ»ç, ÀÓ»ó½ÃÇè¼öʱâ°ü(CRO), Çмú ¹× ¿¬±¸ ±â°üÀÌ Æ÷ÇԵ˴ϴÙ. 2024³â¿¡´Â Á¦¾à ȸ»ç°¡ 46.7%·Î °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇߴµ¥, ÀÌ´Â ÀÓ»ó½ÃÇèÀÇ ÁÖ¿ä ÀÇ·ÚÀڷμ­ÀÇ ÁßÃßÀûÀÎ ¿ªÇÒÀ» ¹Ý¿µÇÏ´Â °á°úÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷µéÀº ´ë±Ô¸ð ÀÓ»ó½ÃÇè¿¡¼­ ¼öÁýÇÑ ¹æ´ëÇÑ ¾çÀÇ »ý¹°ÇÐÀû »ùÇÃÀ» °ü¸®Çϱâ À§ÇØ Ã·´Ü ¹ÙÀÌ¿À¹ðÅ· ¼­ºñ½º¿¡ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. ¼º°øÀûÀÎ ÀÓ»ó½ÃÇè °á°ú¸¦ ´Þ¼ºÇϱâ À§Çؼ­´Â »ùÇà ǰÁú°ú ±ÔÁ¦ Ç¥ÁØ Áؼö°¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2024³â¿¡ 17¾ï ´Þ·¯ ±Ô¸ðÀÇ ½ÃÀåÀ» âÃâÇßÀ¸¸ç, ¹Ì±¹Àº °è¼ÓÇØ¼­ ±Û·Î¹ú ÀÓ»ó ¿¬±¸¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼­ ½Ç½ÃµÇ´Â ÀÓ»ó½ÃÇèÀÇ ¾çÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¤±³ÇÑ ¹ÙÀÌ¿À¹ðÅ· ¹× ¾ÆÄ«À̺ù ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ÀÇ °­·ÂÇÑ ¿¬±¸ ÀÎÇÁ¶ó¿Í Çõ½ÅÀûÀÎ ¹ÙÀÌ¿À¹ðÅ· ±â¼ú¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ´Â ½ÃÀå ¼ºÀåÀÇ ÇÙ½É µ¿·ÂÀ¸·Î¼­ ¹Ì±¹ÀÇ ÀÔÁö¸¦ °ø°íÈ÷ Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • ¾÷°è¿¡ ¹ÌÄ¡´Â ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ÀÓ»ó ½ÃÇè Áõ°¡
      • ¾ö°ÝÇÑ ±ÔÁ¤ Áؼö¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
      • Àå±â µ¥ÀÌÅÍ ÀúÀå ¹× º¸Á¸¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
      • ¹ÙÀÌ¿À¹ðÅ· ÀÎÇÁ¶ó ÅõÀÚ Áõ°¡
    • ¾÷°èÀÇ ÀáÀçÀû À§Çè ¹× °úÁ¦
      • µ¥ÀÌÅÍ º¸¾È ¹× ¾ÈÀü°ú °ü·ÃµÈ ¿ì·Á »çÇ×
      • °í±Þ ÀúÀå ½Ã¼³ÀÇ ÀÚº» Áý¾àÀû Ư¼º
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • °¸ ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • ±â¼úÀû Àü¸Á
  • Àå·¡ ½ÃÀå µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼Ò°³
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« Àü¸Á

Á¦5Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : Á¦Ç° À¯Çüº°(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • ÀüÀÓ»ó Á¦Ç°
  • ÀÓ»ó Á¦Ç°
    • ÀÎÅ× Á¶Á÷
    • Àå±â
    • Áٱ⼼Æ÷
    • ±âŸ ÀÓ»ó Á¦Ç°

Á¦6Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ¼­ºñ½ºº°(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • ¹ÙÀÌ¿À¹ðÅ· ¼­ºñ½º
    • â°í º¸°ü
    • »ùÇà ó¸®
    • ¿î¼Û
    • ±âŸ ¼­ºñ½º
  • ¾ÆÄ«ÀÌºê ¼Ö·ç¼Ç ¼­ºñ½º
    • µ¥ÀÌÅͺ£À̽º Àε¦½Ì ¹× °ü¸®
    • ½ºÄµ ¹× ÆÄ±â

Á¦7Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ÆäÀÌÁ(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • ÀüÀÓ»ó
  • 1»ó
  • 2»ó
  • 3»ó
  • 4»ó

Á¦8Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • Á¦¾à ±â¾÷
  • »ý¸í °øÇÐ ±â¾÷
  • ¼öŹ ¿¬±¸ ±â°ü
  • Çмú ¿¬±¸ ±â°ü

Á¦9Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : Áö¿ªº°(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)

Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • American Type Culture Collection
  • Azenta US Inc.
  • BioStorage Technologies
  • Celerion
  • Celerion
  • Charles River Laboratories
  • CryoPort
  • Hamilton Company
  • IQVIA
  • Labcorp
  • NMDP BioTherapies
  • STC Biologics
  • Thermo Fisher Scientific
  • Veristat
  • VWR International(Avantor)
HBR 25.04.24

The Global Clinical Trial Biorepository And Archiving Solutions Market was valued at USD 4.6 billion in 2024 and is projected to grow at a robust CAGR of 8.3% from 2025 to 2034. This growth is fueled by several critical factors, including the surging number of clinical trials, stringent regulatory compliance requirements, rising demand for long-term data storage, and increased investments in advanced biobanking infrastructure. As the biopharmaceutical sector continues to evolve with groundbreaking developments in drug discovery and personalized medicine, the role of biorepositories in safeguarding critical biological samples has become indispensable. This trend underscores the expanding need for innovative solutions that can cater to the high-volume demands of global clinical trials.

Clinical Trial Biorepository and Archiving Solutions Market - IMG1

The increasing prevalence of chronic diseases and the demand for cutting-edge therapies drive pharmaceutical and biopharmaceutical companies to accelerate their research and development efforts. These companies are not only spearheading the surge in clinical trials but also investing heavily in state-of-the-art biobanking and archiving systems. Such systems are crucial for maintaining the quality, safety, and integrity of biological samples required for rigorous testing of novel treatments. Moreover, technological advancements in biorepository solutions, such as automated storage systems and advanced tracking capabilities, further boost the market's appeal.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$4.6 Billion
Forecast Value$10.1 Billion
CAGR8.3%

The market is segmented by product type into preclinical and clinical products, with the clinical products segment dominating at 73.7% of the market share in 2024. This segment encompasses human tissues, organs, stem cells, and other biological materials that are vital for testing the efficacy and safety of new drugs. The growing complexity of clinical trials and the need to preserve these biological samples underscore the importance of robust storage and management solutions.

End users of biorepository and archiving solutions include pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and academic and research institutions. In 2024, pharmaceutical companies held the largest market share at 46.7%, reflecting their pivotal role as primary sponsors of clinical trials. These companies rely on advanced biorepository services to manage the vast volumes of biological samples collected during large-scale clinical studies. Ensuring sample quality and compliance with regulatory standards is critical to achieving successful trial outcomes.

The U.S. market generated USD 1.7 billion in 2024, with the country continuing to lead global clinical research efforts. The growing volume of clinical trials conducted in the U.S. has created an unparalleled demand for sophisticated biorepository and archiving solutions. The nation's strong research infrastructure, coupled with significant investments in innovative biobanking technologies, solidifies its position as a key driver of market growth.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rise in clinical trials
      • 3.2.1.2 Growing demand for adhering to stringent regulations
      • 3.2.1.3 Increasing demand for long term data storage and preservation
      • 3.2.1.4 Increasing investments in biobanking infrastructure
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Concerns related to data security and safety
      • 3.2.2.2 Capital intensive nature of advanced storage facilities
  • 3.3 Growth potential analysis
  • 3.4 Gap analysis
  • 3.5 Regulatory landscape
  • 3.6 Technological landscape
  • 3.7 Future market trends
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy outlook

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Preclinical products
  • 5.3 Clinical products
    • 5.3.1 Human tissue
    • 5.3.2 Organs
    • 5.3.3 Stem cells
    • 5.3.4 Other clinical products

Chapter 6 Market Estimates and Forecast, By Services, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Biorepository services
    • 6.2.1 Warehousing and storage
    • 6.2.2 Sample processing
    • 6.2.3 Transportation
    • 6.2.4 Other services
  • 6.3 Archiving solution services
    • 6.3.1 Database indexing and management
    • 6.3.2 Scanning and destruction

Chapter 7 Market Estimates and Forecast, By Phase, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Preclinical
  • 7.3 Phase I
  • 7.4 Phase II
  • 7.5 Phase III
  • 7.6 Phase IV

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Pharmaceutical companies
  • 8.3 Biotechnology companies
  • 8.4 Contract research organizations
  • 8.5 Academic and research institutions

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 American Type Culture Collection
  • 10.2 Azenta US Inc.
  • 10.3 BioStorage Technologies
  • 10.4 Celerion
  • 10.5 Celerion
  • 10.6 Charles River Laboratories
  • 10.7 CryoPort
  • 10.8 Hamilton Company
  • 10.9 IQVIA
  • 10.10 Labcorp
  • 10.11 NMDP BioTherapies
  • 10.12 STC Biologics
  • 10.13 Thermo Fisher Scientific
  • 10.14 Veristat
  • 10.15 VWR International (Avantor)
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦